WE ARE PIONEERING THE UNDERSTANDING OF THE NON-CODING, REGULATORY REGION OF THE GENOME TO ADVANCE A NEW WAVE OF MEDICINES DESIGNED TO CONTROL THE EXPRESSION OF DISEASE-DRIVING GENES.

Syros has built a proprietary gene control platform designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, we believe our gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of therapeutic areas and diseases.

Syros is focused on cancer and immune-mediated diseases, and we are building a pipeline of gene control medicines, including our two lead programs SY-1425, an oral, potent and selective RARa agonist that we are initially developing in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and SY-1365, a highly potent and selective CDK7 inhibitor that we are initially developing in certain solid tumors.

Using our platform, we are also generating a pipeline of novel drug candidates in earlier stages of research and development for genomically defined subsets of currently underserved patients.

.